David Smith
Cardiovascular Disease · Winston Salem, NCNPI 1780780031
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.2%), travel and lodging and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Abbott at 32.1% of the total. Reporting peaked in 2024 at $2,312 and has fallen 90.9% since, to $211 in 2025.
Across 82 payments — averaging $57.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Cvrx, Inc.$1K
- AstraZeneca$543
- Boehringer Ingelheim$357
- Amgen$139
- Bayer$134
- plus $590 from 18 others
Across 133 payments — averaging $10,203 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$544K
- AstraZeneca$465K
- American Regent$172K
- Cipla USA Inc.$143K
- Novartis$20K
- Mylan Specialty L.p.$10K
- plus $3K from 1 others
What the payments were for
- Travel & lodging$1,89940%
- Food & beverage$2,79059%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 14 | $1,514 |
| Cvrx, Inc. | 10 | $1,439 |
| AstraZeneca | 12 | $543 |
| Boehringer Ingelheim | 10 | $357 |
| Amgen | 5 | $139 |
| Bayer | 2 | $134 |
| Novo Nordisk | 5 | $94 |
| Esperion Therapeutics, Inc. | 1 | $76 |
| Indivior Inc. | 4 | $65 |
| Johnson & Johnson | 2 | $55 |
| Medtronic | 2 | $41 |
| Gilead | 1 | $34 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $29 |
| United Therapeutics Corporation | 1 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $24 |
| Janssen Scientific Affairs, LLC | 1 | $24 |
| Lundbeck LLC | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Novartis | 1 | $14 |
| Merck | 1 | $14 |
| Pfizer | 1 | $13 |
| Bardy Diagnostics, Inc. | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Confirm Rx$1,121
- Barostim Neo System$1,082
- JARDIANCE$122
- Kerendia$121
- FARXIGA$118
How this compares
$4,716 in reported general payments places this provider in the 65th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 13 | $12,232 |
| EntrestoSacubitril/Valsartan | 11 | $7,287 |
| EliquisApixaban | 11 | $6,325 |
| Amlodipine Besylate | 20 | $168 |
| Carvedilol | 20 | $167 |
| Torsemide | 12 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $94 | $12,23213 claims |
| NovartisEntresto | $14 | $7,28711 claims |
| PfizerEliquis | $13 | $6,32511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Winston Salem
- Dalane KitzmanWinston Salem$199K
- George BodziockWinston Salem$54K
- Patrick KozakWinston Salem$44K
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Michael RinaldiCharlotte$722K
- Markus SchererCharlotte$526K
- Robert MentzDurham$489K
- Sean PokorneyMorganton$477K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.